Loading stock data…
Omeros Corporation (OMER)
$9.79-0.49 (-4.77%)
Market ClosedLast close Jul 24
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Omeros Corporation in the Healthcare sector is trading at $9.79 with a market capitalization of $648M. Wall Street consensus targets $33.00 (1 analysts), implying a +237.1% move over the next 12 months. The stock is currently 45% below its 52-week high of $17.65, remaining 9.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +237.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.89M | $0 | $0 | $0 | $0 |
| Gross Profit | $9.31M | — | — | — | $0 |
| Operating Income | -$17.42M↑ | -$29.08M↓ | -$26.39M↑ | -$32.35M↑ | -$34.97M |
| Net Income | $56.06M↓ | $86.45M↑ | -$30.92M↓ | -$25.42M↑ | -$33.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narso...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$648.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-136.06%
Volume
Today's trading volume
768,673
Recent News
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return
Omeros Corp. (NASDAQ:OMER) is one of the 10 best stocks under $10 that could triple. On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use’s (CHMP) review of a marketing authorization application for the company’s narsoplimab. This antibody targets MASP-2 to cure hematopoietic stem cell transplant-related thrombotic […]
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
Heartflow boasts rapid AI-driven growth but faces reimbursement headwinds, while Omeros bets everything on its first commercial launch.
Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?
Omeros Corporation (NASDAQ:OMER) is among the best get rich quick stocks to buy right now. On June 26, Brandon Folkes from H.C. Wainwright trimmed the price target on Omeros Corporation (NASDAQ:OMER) to $33 from $40 and reaffirmed a Buy rating. This price revision follows a “disappointing” negative CHMP opinion for Yartemlea. While the news is […]
Why Is OMER Stock Falling Today?
European regulators issued a negative opinion on Yartemlea, Omeros’ therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.